Inhibrx Biosciences, Inc. (INBX) - Total Liabilities
Based on the latest financial reports, Inhibrx Biosciences, Inc. (INBX) has total liabilities worth $205.00 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Inhibrx Biosciences, Inc. (INBX) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Inhibrx Biosciences, Inc. - Total Liabilities Trend (2016–2025)
This chart illustrates how Inhibrx Biosciences, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see INBX current and non-current assets.
Inhibrx Biosciences, Inc. Competitors by Total Liabilities
The table below lists competitors of Inhibrx Biosciences, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Westamerica Bancorporation
NASDAQ:WABC
|
USA | $5.03 Billion |
|
Norion Bank
ST:NORION
|
Sweden | Skr59.18 Billion |
|
Taiwan Fertilizer Co Ltd
TW:1722
|
Taiwan | NT$30.21 Billion |
|
PC Jeweller Limited
NSE:PCJEWELLER
|
India | Rs12.51 Billion |
|
Guangdong Golden Dragon Development Inc
SHE:000712
|
China | CN¥18.69 Billion |
|
REDOX Ltd
AU:RDX
|
Australia | AU$187.94 Million |
|
Loma Negra Compania Industrial Argentina SA ADR
NYSE:LOMA
|
USA | $874.99 Billion |
|
Nan Pao Resins Chemical Co Ltd
TW:4766
|
Taiwan | NT$14.72 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Inhibrx Biosciences, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Inhibrx Biosciences, Inc. to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -9.75 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inhibrx Biosciences, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inhibrx Biosciences, Inc. (2016–2025)
The table below shows the annual total liabilities of Inhibrx Biosciences, Inc. from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $138.49 Million | +193.51% |
| 2024-12-31 | $47.18 Million | -82.15% |
| 2023-12-31 | $264.39 Million | +13.56% |
| 2022-12-31 | $232.82 Million | +137.41% |
| 2021-12-31 | $98.07 Million | +43.65% |
| 2020-12-31 | $68.27 Million | -43.14% |
| 2019-12-31 | $120.06 Million | +77.53% |
| 2018-12-31 | $67.63 Million | +70.49% |
| 2017-12-31 | $39.67 Million | +98.00% |
| 2016-12-31 | $20.03 Million | -- |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-bas… Read more